Analyst firm Crude Value Insights downgraded Alexandria Real Estate Equities to Buy from a higher rating, citing recent asset dispositions and intensifying competition in the life sciences real estate sector. Over the past twelve months, ARE sold $500 million of non-core properties, contributing to a 4% decline in year-over-year revenue and a 6% drop in operating cash flow. Despite these headwinds, the company maintains a 91% portfolio occupancy rate and has retained over 80% of expiring leases, underscoring the resilience of its megacampus model in key innovation clusters such as Boston, San Diego and the San Francisco Bay Area.

Management has accelerated the divestiture of non-strategic assets, targeting an additional $300 million of sales by mid-2026, and has trimmed capital expenditure guidance by 15% to preserve liquidity. These measures aim to strengthen the balance sheet ahead of a wave of deliveries expected from 2027 onward. ARE projects incremental net operating income of $240 million from its development pipeline starting in 2027, which management believes will drive FFO growth and reduce net debt to adjusted EBITDA toward its 5.0x target by year-end 2027.

ARE is set to report fourth-quarter results on January 26, with consensus estimates forecasting a low-single-digit decline in same-property rental revenue and a 3% drop in adjusted funds from operations compared to Q4 2024. Analysts point to softened leasing spreads in suburban markets and increased tenant incentives—now averaging $75 per square foot—as key headwinds. On the positive side, management expects to maintain its high occupancy through a combination of early lease renewals and targeted leasing campaigns in growth corridors.

While ARE’s long-term thesis remains supported by secular demand for lab and R&D space, investors should monitor the pace of capitalization rate expansion, which has risen 50 basis points over the last six months to 6.2%, and the company’s ability to stabilize leasing spreads in 2026. Further asset sales carry execution risk, and any delays in the development pipeline could push incremental NOI generation beyond the 2027 timeframe. However, if management delivers on its deleveraging plan and new supply absorption exceeds current forecasts, ARE could see a rerating back to premium valuation levels in late 2026.